Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q2 2017 call → NOThe question asks whether management explains the company's business direction by narrating what its counterparties are themselves doing and scaling — i.e., whether a substantial part of the forward account consists of reporting on the growth/expansion of specific customers, partners, etc., that the company already supplies, such that the company's own coming volume is presented as a consequence of those parties' trajectories. Looking at the transcript, management's forward account is almost entirely about its own actions: portfolio management principles, SKU optimization, pricing/trade discipline, supply chain productivity, SG&A reductions, innovation pipeline, A&P investment, M&A, divestitures. The discussion of volume declines is attributed to the company's own deliberate actions (walking away from low-margin volume, reducing promotions, SKU rationalization). There is no narration of specific customers' or partners' own expansion plans, ramps, rollouts, or build-outs that would drive ConAgra's volume. The only counterparties mentioned are: Ardent Mills JV (a joint venture, not a customer), Rick Bayless (Frontera acquisition integration), and customers generally (retailers) — but there's no description of retailers' own trajectories driving ConAgra's business. The company's outlook is explained through its own strategy execution, not through reporting on someone else's growth. Therefore, the answer is NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.